Baseline and On-Treatment Characteristics of HBeAg-Positive Patients and Correlates of HBeAg Loss Following GS-2829 and GS-6779 Therapeutic Vaccination in Virally Suppressed Patients With Chronic Hepatitis B

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Baseline and On-Treatment Characteristics of HBeAg-Positive Patients and Correlates of HBeAg Loss Following GS-2829 and GS-6779 Therapeutic Vaccination in Virally Suppressed Patients With Chronic Hepatitis B

	EASL 2026 May 26-30 Barcelona Rachel Wen-Juei Jeng1,